CERo Therapeutics Advances Phase 1 Trial with Second Patient Dosed in Cohort 2 — CERo Therapeutics Holdings, Inc.

Event summary

CERo Therapeutics dosed the second patient in Cohort 2 of its Phase 1 CER-1236 trial, marking the fifth patient overall.
The trial is evaluating safety and preliminary efficacy of CER-1236 in hematologic malignancies, including AML, with planned expansion into MDS and MF.
No cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported to date.
One patient with inv(3) AML experienced 72 consecutive days of platelet transfusion independence after four infusions.

The big picture

CERo Therapeutics is advancing its proprietary Chimeric Engulfment Receptor T cell (CER-T) platform, which aims to combine innate and adaptive immunity for more versatile cancer therapy. The ongoing Phase 1 trial represents a critical step in validating this approach against hematologic malignancies, with potential implications for both liquid and solid tumors. The company's ability to expand into high-unmet-need indications like MDS and MF could significantly broaden its market opportunity.

What we're watching

Trial Expansion: Whether the planned expansion into MDS and MF populations will yield similar safety and efficacy profiles as seen in AML.
Dose Escalation: The pace at which CERo Therapeutics can safely escalate dosing while maintaining favorable pharmacokinetic and pharmacodynamic endpoints.
Clinical Activity: How the observed platelet transfusion independence in one patient will translate into broader clinical activity metrics across additional patients.